Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.

Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit.

Sanofi has committed up to $805 million to license multiple sclerosis drug PRN2246 from Principia Biopharma.

Kerrisdale Capital Management, known for its activist short positions, has given Prothena the unwanted title of the “next big biotech blowup.”

It’s a depressingly familiar story in Alzheimer’s R&D: a lot of hype, sprinkles of hope, but then dashed when data day comes around.

Bay area biotech AvidBiotics has decided that its two development programs would do better as separate companies.

AstraZeneca has enlisted the aid of Incyte to try to boost its ambitions in a category of lung cancer immunotherapy where it has a lead over competitors.

Sarepta has been signing a series of new R&D pacts since its controversial DMD drug approval last fall, and today it’s penned a deal for one of the hottest…